Authors: Davies, CD Marsden, SP Stokes, ESE

Citation: Cd. Davies et al., Enhanced asymmetric induction in cycloadditions to bridgehead-chiral vinyldioxazaborocines, TETRAHEDR L, 41(21), 2000, pp. 4229-4233

Authors: Brown, GR Hollinshead, DM Stokes, ESE Waterson, D Clarke, DS Foubister, AJ Glossop, SC McTaggart, F Mirrlees, DJ Smith, GJ Wood, R

Citation: Gr. Brown et al., A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase, J MED CHEM, 43(26), 2000, pp. 4964-4972

Authors: Wedge, SR Ogilvie, DJ Dukes, M Kendrew, J Curwen, JO Hennequin, LF Thomas, AP Stokes, ESE Curry, B Richmond, GHP Wadsworth, PF

Citation: Sr. Wedge et al., ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy, CANCER RES, 60(4), 2000, pp. 970-975

Authors: Brown, GR Hollinshead, DM Stokes, ESE Clarke, DS Eakin, MA Foubister, AJ Glossop, SG Griffiths, D Johnson, MC McTaggart, F Mirrlees, DJ Smith, GJ Wood, R

Citation: Gr. Brown et al., Quinuclidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase: Optimization from lipid profiles, J MED CHEM, 42(7), 1999, pp. 1306-1311

Authors: Hennequin, LF Thomas, AP Johnstone, C Stokes, ESE Ple, PA Lohmann, JJM Ogilvie, DJ Dukes, M Wedge, SR Curwen, JO Kendrew, J Lambert-van der Brempt, C

Citation: Lf. Hennequin et al., Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors, J MED CHEM, 42(26), 1999, pp. 5369-5389